CapitalBio Genotype and Drug Resistance Detection Kit for Hepatitis B Virus

Descriptions The WHO identifies Hepatitis B as a major global health problem. According to the WHO, approximately 240 million individuals are chronically infected with hepatitis B. Each year, there are 780,000 deaths resulting from hepatitis B infection. CapitalBio Genotype and Drug Resistance Detection Kit for Hepatitis B Virus is designed for a rapid and accurate

CapitalBio Thalassemia Gene Mutations Detection Kit

Descriptions CapitalBio Thalassemia Gene Mutations Detection Kit is designed for a rapid and accurate genotyping of Thalassemia. Thalassemia is one of the most common monogenic hereditary blood diseases. It is caused by the deletion of or the mutation in globin-encoding genes which leads to hemolytic anemia. Its symptoms include bone deformities, enlarged spleen, iron overload,

CapitalBio HPV DNA Detection Kit & CapitalBio HPV Genotyping Detection Kit

Descriptions Cervical cancer is one of the major threats to women’s health. According to the WHO, there are 500,000 new incidences and 250,000 deaths resulting from it every year around the world. IARC identifies HPV as the main cause of cervical cancer. Molecular epidemiological investigations demonstrate that DNA fragments of HPV could be detected in

CapitalBio Tuberculosis and Non-Tuberculous Mycobacteria Real-Time PCR Detection Kit & CapitalBio M.

Descriptions The WHO ranks Tuberculosis as “the second leading cause of death from a single infectious agent”. It is estimated that in 2013, there were 9 million new TB cases and 1.1 million deaths resulting from TB worldwide. To make the situation worse, the problem of multidrug resistance is increasingly severe. According to the WHO,

CapitalBio Aminoglycoside-Induced Deafness Gene Mutations Detection Kit

Descriptions According to the WHO, 360 million individuals, or more than 5% of the world’s population, suffers disabling hearing loss. Hearing loss produces significant negative impacts on individuals’ lives as well as on society. Aminoglycoside-Induced Deafness Gene Mutations Detection Kit is designed for a rapid and accurate detection of gene mutations related to deafness caused

CapitalBio Fifteen Deafness-Related Gene Mutations Detection Kit

Descriptions According to the WHO, 360 million individuals, or more than 5% of the world’s population, suffer disabling hearing loss. Hearing loss produces significant negative impacts on individuals’ life and society. Fifteen Deafness-Related Gene Mutations Detection Kit is designed for a rapid and accurate detection of deafness-related gene mutations. It employs multiplex allele-specific PCR-based universal

Chat Zalo Hotline: 0988016801